Phase 1/2 Open-Label Trial to Assess the Safety and Preliminary Efficacy of 177Lu-OPS201 as Peptide Receptor Radionuclide Therapy in Patients With Somatostatin Receptor-Positive, Progressive Neuroendocrine Tumors

被引：0
|
作者：
Nicolas, Guillaume [1 ,2 ]
Bodei, Lisa [3 ]
Baum, Richard [4 ]
Herrmann, Ken [5 ]
Lassmann, Michael [6 ]
Hicks, Rodney [7 ]
Navalkissoor, Shaunak [2 ]
Haug, Alexander [8 ]
Oberwittler, Heike [9 ]
Wang, Tiffany [10 ]
Wild, Damian [1 ]
机构：
[1] Univ Basel Hosp, Basel, Switzerland
[2] Royal Free Hosp, London, England
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Zent Klin Bad Berka, Bad Berka, Germany
[5] Univ Calif Los Angeles, Los Angeles, CA USA
[6] Univ Hosp Wurzburg, Wurzburg, Germany
[7] Peter MacCallum Canc Ctr, East Melbourne, Australia
[8] Med Univ Vienna, Vienna, Austria
[9] Ipsen, Les Ulis, France
[10] Ipsen, Cambridge, MA USA
来源：
PANCREAS | 2018年 / 47卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：349 / 349
页数：1
相关论文
共 50 条
  • [1] Phase 1/2 open-label trial to assess the safety and preliminary efficacy of 177Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours
    Nicolas, G.
    Baum, R. P.
    Herrmann, K.
    Lassmann, M.
    Hicks, R. J.
    Haug, A. R.
    Navalkissoor, S.
    Oberwittler, H.
    Wang, T.
    Wild, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S772 - S772
  • [2] Peptide Receptor Radionuclide Therapy (PRRT) with a Somatostatin Receptor (SSTR) Antagonist in Patients with SSTR-Positive, Progressive Neuroendocrine Tumours (NETs): A Phase I/II Open-Label Trial to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201
    Nicolas, G.
    Baum, R.
    Herrmann, K.
    Lassmann, M.
    Hicks, R.
    Haug, A. R.
    Oberwittler, H.
    Bouterfa, H.
    Wang, T.
    Wild, D.
    NEUROENDOCRINOLOGY, 2017, 105 : 250 - 250
  • [3] OPS-C-001: A Phase I/II Study to Investigate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor (SSTR)-Positive Neuroendocrine Tumours (NETs)
    Nicolas, G.
    Baum, R. P.
    Herrmann, K.
    Lassmann, M.
    Hicks, R.
    Haug, A.
    Wahba, M.
    Wang, T.
    Wild, D.
    NEUROENDOCRINOLOGY, 2019, 108 : 224 - 224
  • [4] Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors
    Noritoshi Kobayashi
    Shoko Takano
    Kenichi Ito
    Madoka Sugiura
    Matsuyoshi Ogawa
    Yuma Takeda
    Naoki Okubo
    Akihiro Suzuki
    Motohiko Tokuhisa
    Tomohiro Kaneta
    Daisuke Utsunomiya
    Masaharu Hata
    Tomio Inoue
    Makoto Hosono
    Seigo Kinuya
    Yasushi Ichikawa
    Annals of Nuclear Medicine, 2021, 35 : 1332 - 1341
  • [5] Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors
    Kobayashi, Noritoshi
    Takano, Shoko
    Ito, Kenichi
    Sugiura, Madoka
    Ogawa, Matsuyoshi
    Takeda, Yuma
    Okubo, Naoki
    Suzuki, Akihiro
    Tokuhisa, Motohiko
    Kaneta, Tomohiro
    Utsunomiya, Daisuke
    Hata, Masaharu
    Inoue, Tomio
    Hosono, Makoto
    Kinuya, Seigo
    Ichikawa, Yasushi
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (12) : 1332 - 1341
  • [6] Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors
    Abou Jokh Casas, E.
    Pombo Pasin, M. D.
    Pubul Nunez, V.
    Garrido Pumar, M.
    Blanco Freire, M. N.
    Cabezas, J.
    Cameselle, J.
    Berrios, M.
    Argibay, S.
    Ruibal Morell, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S597 - S598
  • [7] Safety and efficacy of peptide receptor radionuclide therapy with 177 Lu-DOTA 0-Tyr 3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors
    Kobayashi, N.
    Takano, S.
    Ito, K.
    Sugiura, M.
    Ogawa, M.
    Takeda, Y.
    Okubo, N.
    Suzuki, A.
    Tokuhisa, M.
    Kaneta, T.
    Utsunomiya, D.
    Hata, M.
    Inoue, T.
    Hosono, M.
    Kinuya, S.
    Ichikawa, Y.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 149 - 149
  • [8] Phase 1 Study of No-Carrier Added 177Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor-Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea
    Ryoo, Hyun Gee
    Suh, Minseok
    Kang, Keon Wook
    Lee, Dae-Won
    Han, Sae-Won
    Cheon, Gi Jeong
    CANCER RESEARCH AND TREATMENT, 2023, 55 (01): : 334 - 343
  • [9] Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor-Expressing Neuroendocrine Tumors The First US Phase 2 Experience
    Delpassand, Ebrahim S.
    Samarghandi, Amin
    Zamanian, Sara
    Wolin, Edward M.
    Hamiditabar, Mohammadali
    Espenan, Gregory D.
    Erion, Jack L.
    O'Dorisio, Thomas M.
    Kvols, Larry K.
    Simon, Jaime
    Wolfangel, Robert
    Camp, Arthur
    Krenning, Eric P.
    Mojtahedi, Alireza
    PANCREAS, 2014, 43 (04) : 518 - 525
  • [10] Safety and response after peptide receptor radionuclide therapy with 177Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial
    Kudo, Atsushi
    Tateishi, Ukihide
    Yoshimura, Ryoichi
    Tsuchiya, Junichi
    Yokoyama, Kota
    Takano, Shoko
    Kobayashi, Noritoshi
    Utsunomiya, Daisuke
    Hata, Masaharu
    Ichikawa, Yasushi
    Tanabe, Minoru
    Hosono, Makoto
    Kinuya, Seigo
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2022, 29 (04) : 487 - 499
12345